Biotech Ab Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Annual Report 2020 Active Biotech AB (publ)

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Annual Report 2020 Active Biotech AB (publ) Active BiotechApril 22, 2021 GMT Active Biotech’s Annual Report 2020 is now available for download at www.activebiotech.com. The Annual Report will only be digitally distributed. Helén Tuvesson, CEO, tel. +46 46 19 21 56, helen.tuvesson@activebiotech.com Hans Kolam, CFO, tel. +46 46 19 20 44, hans.kolam@activebiotech.com ADVERTISEMENT Scheelevägen 22, 223 63 Lund, Sweden Tel. +46 46-19 20 00 This information is information that Active Biotech AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 11.00 a.m. CET on April 22, 2021.

Hans kolamBiotech ab corpActive biotechAnnual reportSecurities marketsNasdaq stockholmஹான்ஸ் கோலம்பயோடெக் அப கார்ப்செயலில் பயோடெக்ஆண்டு அறிக்கைபத்திரங்கள் சந்தைகள்நாஸ்டாக் ஸ்டாக்‌ஹோல்ம்

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

Message : Required fields Phase IIa trial in non-small cell lung cancer expected to begin enrollment in the US in the second half of 2021 Lund Sweden, April 19, 2021 - Active Biotech AB (publ) (NASDAQ STOCKHOLM: ACTI) and NeoTX today announced that they have received clearance from the U.S. Food and Drug Administration (FDA) for the Investigational New Drug (IND) application of the tumor targeted superantigen naptumomab estafenatox (Naptumomab). The Phase IIa open label trial will evaluate naptumomab in combination with docetaxel in 35 patients with checkpoint inhibitor pretreated, advanced or metastatic non-small cell lung cancer. The primary endpoint is objective response rate as measured by RECIST 1.1 criteria. The trial will also evaluate safety, duration of response, progression free survival, pharmacokinetics and pharmacodynamics.

Hans kolamDrug administrationBiotech ab corpBiotech to neotx therapeutics ltdInvestigational new drugActive biotechNasdaq stockholmTumor targeted superantigenஹான்ஸ் கோலம்பயோடெக் அப கார்ப்செயலில் பயோடெக்நாஸ்டாக் ஸ்டாக்‌ஹோல்ம்

Investegate |Active Biotech Announcements | Active Biotech: Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, 220 07 Lund, Sweden +46 46-19 20 00 www.activebiotech.com This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 08.30 a.m. CET on April 19, 2021. Active Biotech Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumom

Hans kolamDrug administrationBiotech ab corpBiotech to neotx therapeutics ltdActive biotechInvestigational new drugNasdaq stockholmTumor targeted superantigenInvestegate announcementsInvestegate company announcementsActive biotechLobenewswire and globenewswireஹான்ஸ் கோலம்பயோடெக் அப கார்ப்செயலில் பயோடெக்நாஸ்டாக் ஸ்டாக்‌ஹோல்ம்

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Hans kolamDrug administrationBiotech ab corpBiotech to neotx therapeutics ltdInvestigational new drugActive biotechNasdaq stockholmTumor targeted superantigenஹான்ஸ் கோலம்பயோடெக் அப கார்ப்செயலில் பயோடெக்நாஸ்டாக் ஸ்டாக்‌ஹோல்ம்

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab

Active Biotech and NeoTX announce FDA Clearance of IND for Phase II Clinical Trial of Naptumomab
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.